Demographics | Ulcerative colitis | Crohn’s disease | P value |
Participants, no (%) | 13 (50) | 13 (50) | N/A |
Age, years, median (IQR) | 43 (36–49) | 42 (39–51) | 0.78 |
Women (cisgender), no (%) | 9 (69) | 8 (62) | 1.00 |
Disease duration, years, median (IQR) | 11 (5–15) | 17 (12–20) | 0.05 |
Montreal classification, no (%) | N/A | ||
Ulcerative colitis | |||
Disease location | |||
E1 ulcerative proctitis | 1 (8) | – | |
E2 left-sided | 8 (61) | – | |
E3 extensive | 4 (31) | – | |
Severity | |||
S0 remission | 4 (31) | – | |
S1 mild | 4 (31) | – | |
S2 moderate | 5 (38) | – | |
S3 severe | 0 | ||
Crohn’s disease | |||
Age at diagnosis | |||
A1 <16 years | – | 3 (23) | |
A2 17–40 years | – | 7 (54) | |
A3 >40 years | – | 3 (23) | |
Disease location | |||
L1 terminal ileum | – | 2 (15) | |
L2 colon | – | 4 (31) | |
L3 ileocolonic | – | 5 (38) | |
L4 isolated upper disease | – | 1 (8) | |
L2+L4 colon+upper disease | – | 1 (8) | |
Behaviour | |||
B1 non-stricturing, non-penetrating | – | 4 (31) | |
B2 stricturing | – | 6 (46) | |
B3 penetrating | – | 0 | |
p* penetrating perianal | – | 3 (23) | |
Treatment, no (%) | 0.84 | ||
Only biologics | 8 (61) | 6 (46) | |
Only thiopurines | 1 (8) | 1 (8) | |
Biologics+thiopurines | 4 (31) | 6 (46) | |
Type of biologic, no (%) | N/A | ||
Infliximab | 8 (61) | 8 (61) | |
Adalimumab | 1 (8) | 3 (23) | |
Vedolizumab | 1 (8) | 1 (8) | |
Golimumab | 2 (15) | 0 | |
Treatment duration biologics, months, median (IQR) | 24 (16–27) | 27 (6–39) | 0.64 |
Concomitant treatment, no (%) | N/A | ||
None (thiopurines not included) | 2 (15) | 13 (100) | |
5-Aminosalicylic acid (5-ASA) | 11 (84) | 0 | |
Previous number of biologics, no, median (IQR) | 0 (0–1) | 1 (0–1) | 0.22 |
Other chronic diseases, no (%) | 5 (38) | 6 (46) | 0.68 |
Patient-reported disease activity, no (%) | |||
Remission | 3 (23) | 9 (69) | 0.06 |
Mild | 2 (15) | 1 (8) | |
Moderate | 7 (54) | 2 (15) | |
Severe | 0 | 1 (8) | |
Unknown | 1 (8) | 0 | |
Fatigue, median VAS (IQR) | 4 (2–5) | 5 (2–7) | 0.48 |
Pain, median VAS (IQR) | 2 (0–3) | 2 (1–3) | 0.79 |
Work status, no (%) | 0.5 | ||
Employed | 9 (69) | 9 (69) | |
Part-time employed | 2 (15) | 2 (15) | |
Unemployed | 1 (8) | 2 (15) | |
Student | 1 (8) | 0 |
*Perianal disease modifier.
N/A, not applicable; VAS, visual analogue scale.